Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Solasta Bio Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner within 1 distinct art unit. The examiner, FISCHER, JOSEPH, is responsible for this 1 pending action, which constitutes the company's total current pending workload. This singular focus in 1 distinct art unit indicates a very specific technical area for the company's current patent activity. Practitioners should tailor their approach to the specific requirements of this 1 distinct art unit.
With only 1 pending office action, the company's prosecution success is currently tied to the review of 1 distinct examiner, FISCHER, JOSEPH. The presence of 1 distinct art unit means the company is not currently facing the varied examination standards of multiple patent office divisions. Practitioners can concentrate their efforts on the specific requirements and precedents of this 1 distinct art unit. This streamlined profile suggests that Solasta Bio Limited is currently managing a very focused and limited number of active applications. The outcome of this 1 pending office action will be a key indicator for the company's biotech portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | — |
| 19089551 | INSECT NEUROPEPTIDES 1 | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | 1658 | §101§103§112 | Final Rejection | — | Pending | Mar 25, 2025 |
| 19089551 | INSECT NEUROPEPTIDES 1 | KOMATSU, LI N | 1658 | §103 | Final Rejection | — | Pending | Mar 25, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial